BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 29373100)

  • 1. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
    J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
    Wu L; Zou Z; Li Y; Hao X; Ying J; Li J; Xing P
    J Transl Med; 2024 Jun; 22(1):585. PubMed ID: 38902768
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
    Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
    Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
    Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
    Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
    Elshatlawy M; Sampson J; Clarke K; Bayliss R
    Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
    Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
    Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
    Makimoto G; Ohashi K; Maeda Y; Kiura K
    Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.